Allergan PLC. (AGN) Scheduled to Post Quarterly Earnings on Wednesday
Allergan PLC. (NYSE:AGN) is scheduled to release its earnings data before the market opens on Wednesday, November 1st. Analysts expect Allergan PLC. to post earnings of $4.19 per share for the quarter. Allergan PLC. has set its FY17 guidance at $16.05-16.45 EPS.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the business earned $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, analysts expect Allergan PLC. to post $16.19 EPS for the current fiscal year and $17.41 EPS for the next fiscal year.
Shares of Allergan PLC. (AGN) opened at 182.92 on Wednesday. Allergan PLC. has a 52 week low of $182.78 and a 52 week high of $256.80. The firm has a 50-day moving average price of $209.40 and a 200-day moving average price of $229.47. The stock has a market cap of $61.15 billion, a PE ratio of 5.57 and a beta of 1.15.
Allergan PLC. declared that its Board of Directors has approved a stock repurchase program on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.
AGN has been the subject of several research reports. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a research report on Tuesday, July 11th. Credit Suisse Group set a $288.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research report on Saturday, August 5th. Royal Bank Of Canada set a $285.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Deutsche Bank AG reiterated a “buy” rating and issued a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Mizuho reiterated a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $252.39.
TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Scheduled to Post Quarterly Earnings on Wednesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/25/allergan-plc-agn-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.